المؤلفون: A. A. Ragimova, D. S. Petelin, A. N. Galyautdinova, V. A. Tolmacheva, B. A. Volel, А. А. Рагимова, Д. С. Петелин, А. Н. Галяутдинова, В. A. Толмачева, Б. А. Волель

المصدر: Neurology, Neuropsychiatry, Psychosomatics; Vol 16, No 3 (2024); 38-43 ; Неврология, нейропсихиатрия, психосоматика; Vol 16, No 3 (2024); 38-43 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2024-3

مصطلحات موضوعية: нейропсихиатрия, transcranial magnetic stimulation, non-drug biological therapies, non-motor symptoms, neuropsychiatry, транскраниальная магнитная стимуляция, нелекарственные биологические методы терапии, немоторные симптомы

وصف الملف: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/2277/1664; Ben-Shlomo Y, Camfield L, Warner T; ESDE collaborative group. What are the determinants of quality of life in people with cervical dystonia? Neurol Neurosurg Psychiatry. 2002 May;72(5):608-14. doi:10.1136/jnnp.72.5.608; Van den Dool J, Tijssen MA, Koelman JH, et al. Determinants of disability in cervical dystonia. Parkinsonism Relat Disord. 2016 Nov;32:48-53. doi:10.1016/j.parkreld-is.2016.08.014. Epub 2016 Aug 15.; Mahajan A, Jankovic J, Marsh L, et al.; members of the Dystonia Coalition. Cervical dystonia and substance abuse. Neurol. 2018 Apr;265(4):970-5. doi:10.1007/s00415-018-8840-9. Epub 2018 Mar 22.; Толмачева ВА, Юзбашян ПГ, Петелин ДС идр. Расстройства тревожно-депрессивного спектра при цервикальной дистонии. Неврология, нейропсихиатрия, психосоматика. 2022;14(4):38-43. doi:10.14412/2074-2711-2022-4-38-43; Berardelli I, Ferrazzano G, Pasquini M, et al. Clinical course of psychiatric disorders in patients with cervical dystonia. Psychiatry Res. 2015 Sep 30;229(1-2):583-5. doi:10.1016/j.psychres.2015.07.076. Epub 2015 Jul 29.; Stamelou M, Edwards MJ, Hallett M, Bhatia KP. The non-motor syndrome of primary dystonia: clinical and pathophysiological implications. Brain. 2012 Jun;135(Pt 6):1668-81. doi:10.1093/brain/awr224. Epub 2011 Sep 20.; Нодель МР, Салоухина НИ, Толмачева ВА. Влияние недвигательных расстройств на качество жизни пациентов с цервикальной мышечной дистонией. Неврология, нейропсихиатрия, психосоматика. 2022;14(3):19-25. doi:10.14412/20742711-2022-3-19-25; Ceylan D, Erer S, Zarifoglu M, et al. Evaluation of anxiety and depression scales and quality of LIFE in cervical dystonia patients on botulinum toxin therapy and their relatives. Neurol Sci. 2019 Apr;40(4):725-31. doi:10.1007/s10072-019-3719-9. Epub 2019 Jan 18.; Gundel H, Wolf A, Xidara V, et al. Social phobia in spasmodic torticollis. J Neurol Neurosurg Psychiatry. 2001 Oct;71(4):499-504. doi:10.1136/jnnp.71.4.499; Stein MB, Heuser IJ, Juncos JL, Uhde TW. Anxiety disorders in patients with Parkinson's disease. Am J Psychiatry. 1990 Feb;147(2):217-20. doi:10.1176/ajp.147.2.217; Ortiz RM, Scheperjans F, Mertsalmi T, Pekkonen E. Comorbidity and retirement in cervical dystonia. J Neurol. 2019 Sep;266(9):2216-23. doi:10.1007/s00415-019-09402-0. Epub 2019 May 31.; Brini S, Brudasca NI, Hodkinson A, et al. Efficacy and safety of transcranial magnetic stimulation for treating major depressive disorder: An umbrella review and re-analysis of published meta-analyses of randomised controlled trials. Clin Psychol Rev. 2023 Mar;100:102236. doi:10.1016/j.cpr.2022.102236. Epub 2022 Dec 8.; Pirio Richardson S, Tinaz S, Chen R. Repetitive transcranial magnetic stimulation in cervical dystonia: effect of site and repetition in a randomized pilot trial. PLoS One. 2015 Apr 29;10(4):e0124937. doi:10.1371/journal.pone.0124937; Bradnam LV, McDonnell MN, Ridding MC. Cerebellar Intermittent Theta-Burst Stimulation and Motor Control Training in Individuals with Cervical Dystonia. Brain Sci. 2016 Nov 23;6(4):56. doi:10.3390/brainsci6040056; Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. Psychosom Res. 2002 Feb;52(2):69-77. doi:10.1016/s0022-3999(01)00296-3; LoMartire R, Ang BO, Gerdle B, Vixner L. Psychometric properties of Short Form-36 Health Survey, EuroQol 5-dimensions, and Hospital Anxiety and Depression Scale in patients with chronic pain. Pain. 2020 Jan;161(1):83-95. doi:10.1097/j.pain.0000000000001700; Muller J, Wissel J, Kemmler G, et al. Craniocervical dystonia questionnaire (CDQ-24): development and validation of a disease-specific quality of life instrument. Neurol Neurosurg Psychiatry. 2004 May;75(5):749-53. doi:10.1136/jnnp.2003.013441; De Oliveira Souza C, Goulardins J, Coelho DB, et al. Non-invasive brain stimulation and kinesiotherapy for treatment of focal dystonia: Instrumental analysis of three cases. J Clin Neurosci. 2020 Jun;76:208-10. doi:10.1016/j.jocn.2020.04.025. Epub 2020 Apr 10.; Duarte GS, Rodrigues FB, Ferreira JJ, Costa J. Adverse events with botulinum toxin treatment in cervical dystonia: How much should we blame placebo? Parkinsonism Relat Disord. 2018 Nov;56:16-9. doi:10.1016/j.parkreldis.2018.06.017. Epub 2018 Jun 15.; Hu YT, Hu XW, Han JF, et al. Motor cortex repetitive transcranial magnetic stimulation in major depressive disorder. A preliminary randomized controlled clinical trial. J Affect Disord. 2024 Jan 1;344:169-75. doi:10.1016/j.jad.2023.10.058. Epub 2023 Oct 11.; Berman BD, Junker J, Shelton E, et al. Psychiatric associations of adult-onset focal dystonia phenotypes. Neurol Neurosurg Psychiatry. 2017 Jul;88(7):595-602. doi:10.1136/jnnp-2016-315461. Epub 2017 Apr 24.; https://nnp.ima-press.net/nnp/article/view/2277

الاتاحة: https://nnp.ima-press.net/nnp/article/view/2277
https://doi.org/10.14412/2074-2711-2024-3-38-43

المؤلفون: V. A. Tolmacheva, P. G. Yuzbashyan, D. S. Petelin, B. A. Volel, N. I. Salouhina, M. R. Nodel, D. V. Romanov, В. А. Толмачева, П. Г. Юзбашян, Д. С. Петелин, Б. А. Волель, Н. И. Салоухина, М. Р. Нодель, Д. В. Романов

المصدر: Neurology, Neuropsychiatry, Psychosomatics; Vol 14, No 4 (2022); 38-43 ; Неврология, нейропсихиатрия, психосоматика; Vol 14, No 4 (2022); 38-43 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2022-4

مصطلحات موضوعية: тревожные и депрессивные расстройства, cervical dystonia, motor and non-motor symptoms, anxiety and depressive disorders, цервикальная дистония, моторные и немоторные симптомы

وصف الملف: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/1859/1436; Berman BD, Junker J, Shelton E, et al. Psychiatric associations of adult-onset focal dystonia phenotypes. J Neurol Neurosurg Psychiatry. 2017 Jul;88(7):595-602. doi:10.1136/jnnp-2016-315461. Epub 2017 Apr 24.; Wise MG, Rundell JR. Anxiety and neurological disorders. Semin Clin Neuropsychiatry. 1999 Apr;4(2):98-102. doi:10.1053/SCNP00400098; Medina Escobar A, Pringsheim T, Goodarzi Z, Martino D. The prevalence of depression in adult onset idiopathic dystonia: Systematic review and metaanalysis. Neurosci Biobehav Rev. 2021 Jun;125:221-30. doi:10.1016/j.neubiorev.2021.02.036. Epub 2021 Mar 1.; Albanese A, Bhatia K, Bressman SB, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2013;28(7):863-73. doi:10.1002/mds.25475; Lehn A, Mellick G, Boyle R. Psychiatric disorders in idiopathic-isolated focal dystonia. J Neurol. 2014 Apr;261(4):668-74. doi:10.1007/s00415-014-7244-8. Epub 2014 Jan 22.; Yang J, Shao N, Song W, et al. Nonmotor symptoms in primary adult-onset cervical dystonia and blepharospasm. Brain Behav. 2016 Dec 18;7(2):e00592. doi:10.1002/brb3.592.eCollection 2017 Feb.; Barahona-Correa B, Bugalho P, Guimaraes J, Xavier M. Obsessive-compulsive symptoms in primary focal dystonia: a controlled study. Mov Disord. 2011 Oct;26(12):2274-8. doi:10.1002/mds.23906. Epub 2011 Aug 9.; Ferrazzano G, Berardelli I, Conte A, et al. Motor and non-motor symptoms in blepharospasm: clinical and pathophysiological implications. J Neurol. 2019 Nov;266(11):2780-5. doi:10.1007/s00415-019-09484-w. Epub 2019 Jul 29.; Салоухина НИ, Нодель МР, Толмачева ВА. Недвигательные нарушения у пациентов с мышечной дистонией. Журнал неврологии и психиатрии им. С.С. Корсакова. 2018;118(9):98-105. doi:10.17116/jnevro201811809198; Гусев ЕИ, редактор. Клинические рекомендации по диагностике и лечению дистонии. Всероссийское общество неврологов. Президиум. Москва; 2014.; Тимербаева СЛ, редактор. Азбука ботулинотерапии: научно-практическое издание. Москва: Практическая медицина; 2014. 416 с.; Levis B, Benedetti A, Thombs BD; DEPRESsion Screening Data (DEPRESSD) Collaboration. Accuracy of Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression: individual participant data meta-analysis. BMJ. 2019 Apr 9;365:l1476. doi:10.1136/bmj.l1476. Erratum in: BMJ. 2019 Apr 12;365:l1781.; Donker T, van Straten A, Marks I, Cuijpers P. Quick and easy self-rating of Generalized Anxiety Disorder: validity of the Dutch web-based GAD-7, GAD-2 and GAD-SI. Psychiatry Res. 2011 Jun 30;188(1):58-64. doi:10.1016/j.psychres.2011.01.016. Epub 2011 Feb 19.; Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13. doi:10.1046/j.1525-1497.2001.016009606.x; EuroQol Group. EuroQol – a new facility for the measurement of health-related quality of life. Health Policy. 1990 Dec;16(3):199-208. doi:10.1016/0168-8510(90)90421-9; Junker J, Berman BD, Hall J, et al. Quality of life in isolated dystonia: non-motor manifestations matter. J Neurol Neurosurg Psychiatry. 2021 Feb 9:jnnp-2020-325193. doi:10.1136/jnnp-2020-325193. Epub ahead of print.; Novaretti N, Cunha ALN, Bezerra TC, et al. The Prevalence and Correlation of Non-motor Symptoms in Adult Patients with Idiopathic Focal or Segmental Dystonia. Tremor Other Hyperkinet Mov (N Y). 2019 Feb 4;9:596. doi:10.7916/fhnv-v355; Чернуха ТН, Лихачев СА. Особенности психоэмоционального статуса пациентов с мышечной дистонией. Неврология и нейрохирургия. Восточная Европа (Минск). 2016;6(4):506-15.; Stamelou M, Edwards MJ, Hallett M, Bhatia KP. The non-motor syndrome of primary dystonia: clinical and pathophysiological implications. Brain. 2012 Jun;135(Pt 6):1668-81. doi:10.1093/brain/awr224. Epub 2011 Sep 20.; Van den Dool J, Tijssen MA, Koelman JH, et al. Determinants of disability in cervical dystonia. Parkinsonism Relat Disord. 2016 Nov;32:48-53. doi:10.1016/j.parkreldis.2016.08.014. Epub 2016 Aug 15.; Eichenseer SR, Stebbins GT, Comella CL. Beyond a motor disorder: a prospective evaluation of sleep quality in cervical dystonia. Parkinsonism Relat Disord. 2014;20:405-8. doi:10.1016/j.parkreldis.2014.01.004; Paus S, Gross J, Moll-Müller M, et al. Impaired sleep quality and restless legs syndrome in idiopathic focal dystonia: a controlled study. J Neurol. 2011;258:1835-40. doi:10.1007/s00415-011-6029-6; Толмачева ВА, Нодель МР, Салоухина НИ. Недвигательные нарушения при цервикальной дистонии. Неврология, нейропсихиатрия, психосоматика. 2018;10(3):135-40. doi:10.14412/2074-2711-2018-3-135-140; Дружинина ОА, Жукова НГ, Шперлинг ЛП. Качество жизни при цервикальной дистонии. Бюллетень сибирской медицины. 2020;19(1):43-9. doi:10.20538/1682-0363-2020-1-43-49; Ndukwe I, O'Riordan S, Walsh CB, Hutchinson M. Trust the Patient Not the Doctor: The Determinants of Quality of Life in Cervical Dystonia. Front Neurol. 2020 Sep 4;11:991. doi:10.3389/fneur.2020.00991; Smit M, Kamphuis ASJ, Bartels AL, et al. Fatigue, Sleep Disturbances, and Their Influence on Quality of Life in Cervical Dystonia Patients. Mov Disord Clin Pract. 2016 Dec 5;4(4):517-23. doi:10.1002/mdc3.12459. eCollection Jul-Aug 2017.; Zurowski M, McDonald WM, Fox S, Marsh L. Psychiatric comorbidities in dystonia: emerging concepts. Mov Disord. 2013 Jun 15;28(7):914-20. doi:10.1002/mds.25501; Castelao M, Marques RE, Duarte GS, et al. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev. 2017 Dec 12;12(12):CD003633. doi:10.1002/14651858.CD003633.pub3; Griffiths S, Hay P, Mitchison D, et al. Sex differences in the relationships between body dissatisfaction, quality of life and psychological distress. Aust N Z J Public Health. 2016 Dec;40(6):518-22. doi:10.1111/1753-6405.12538. Epub 2016 Jul 3.; Zoons E, Tijssen MAJ, Dreissen YEM, et al. The relationship between the dopaminergic system and depressive symptoms in cervical dystonia. Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1375-82. doi:10.1007/s00259-017-3664-x. Epub 2017 Mar 17.; Conte A, Berardelli I, Ferrazzano G, et al. Non-motor symptoms in patients with adultonset focal dystonia: sensory and psychiatric disturbances. Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S111-4. doi:10.1016/j.parkreldis.2015.09.001. Epub 2015 Sep 3.; Moll M, Rosenthal D, Hefter H. Quality of life in long-term botulinum toxin treatment of cervical dystonia: Results of a cross sectional study. Parkinsonism Relat Disord. 2018 Dec;57:63-7. doi:10.1016/j.parkreldis.2018.07.019. Epub 2018 Jul 31.; Смулевич АБ, редактор. Психосоматические расстройства. Руководство для практических врачей. Москва: МЕДпресс-инфором; 2000, 73 с.; https://nnp.ima-press.net/nnp/article/view/1859

الاتاحة: https://nnp.ima-press.net/nnp/article/view/1859
https://doi.org/10.14412/2074-2711-2022-4-38-43

المؤلفون: E. V. Yakovenko, F. A. Abbasov, Е. В. Яковенко, Ф. А. Аббасов

المساهمون: This article has been supported by Servier., Статья спонсируется компанией «Сервье».

المصدر: Neurology, Neuropsychiatry, Psychosomatics; Vol 14, No 4 (2022); 103-107 ; Неврология, нейропсихиатрия, психосоматика; Vol 14, No 4 (2022); 103-107 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2022-4

مصطلحات موضوعية: пирибедил, non-motor symptoms, apathy, depression, dementia, piribedil, немоторные симптомы, апатия, депрессия, деменция

وصف الملف: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/1869/1446; Alves G, Forsaa EB, Pedersen KF, et al. Epidemiology of Parkinson's disease. J Neurol. 2008 Sep;255 Suppl 5:18-32. doi:10.1007/s00415-008-5004-3; Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015 Oct;30(12):1591-601. doi:10.1002/mds.26424; Todorova A, Jenner P, Ray Chaudhuri K. Non-motor Parkinson's: integral to motor Parkinson's, yet often neglected. Pract Neurol. 2014 Oct;14(5):310-22. doi:10.1136/practneurol-2013-000741. Epub 2014 Apr 3.; Fox SH, Katzenschlager R, Lim SY, et al. Update on treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2018 Aug;33(8):1248-66. doi:10.1002/mds.27372. Epub 2018 Mar 23.; Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson's disease – an evidencebased medicine review. Mov Disord. 2019 Feb;34(2):180-98. doi:10.1002/mds.27602. Epub 2019 Jan 17.; Титова НВ, Чаудхури КР. Немоторные симптомы болезни Паркинсона: подводная часть айсберга. Анналы клинической и экспериментальной неврологии. 2017;11(4):5-18. doi:10.18454/ACEN.2017.4.1; Schrag A, Ben-Shlomo Y, Quinn N. How common are complications of Parkinson’s disease? J Neurol. 2002 Apr;249(4):419-23. doi:10.1007/s004150200032; Pagonabarraga J, Kulisevsky J, Strafella AP, et al. Apathy in Parkinson’s disease: clinical features, neural substrates, diagnosis, and treatment. Lancet Neurol. 2015 May;14(5):518-31. doi:10.1016/S1474-4422(15)00019-8. Epub 2015 Apr 12.; Santangelo G, Trojano L, Barone P, et al. Apathy in Parkinson's disease: diagnosis, neuropsychological correlates, pathophysiology and treatment. Behav Neurol. 2013 Jan 1;27(4):501-13. doi:10.3233/BEN-129025; Santangelo G, D’Iorio A, Maggi G, et al. Cognitive correlates of “pure apathy” in Parkinson's disease. Parkinsonism Relat Disord. 2018 Aug;53:101-4. doi:10.1016/j.parkreldis.2018.04.023. Epub 2018 Apr 24.; Mentenopoulos G, Katsarou Z, Bostantjopoulou S, et al. Piribedil therapy in Parkinson’s disease. Use of the drug in the retard form. Clin Neuropharmacol. 1989 Feb;12(1):23-8.; Castro-Caldas A, Delwaide P, Jost W, et al. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson’s disease. Mov Disord. 2006 Apr;21(4):500-9. doi:10.1002/mds.20750; Rondot P, Ziegler M. Activity and acceptability of piribedil in Parkinson’s disease: a multicentre study. J Neurol. 1992;239 Suppl 1:S28-34. doi:10.1007/BF00819564; Broen MP, Narayen NE, Kuijf ML, et al. Prevalence of anxiety in Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2016 Aug;31(8):1125-33. doi:10.1002/mds.26643. Epub 2016 Apr 29.; Zhu K, van Hilten JJ, Marinus J. Onset and evolution of anxiety in Parkinson's disease. Eur J Neurol. 2017 Feb;24(2):404-11. doi:10.1111/ene.13217. Epub 2016 Dec 29.; Pertovaara A, Haapalinna A, Sirvio J, et al. Pharmacological properties, central nervous system effects, and potential therapeutic applications of atipamezole, a selective alpha2-adrenoceptor antagonist. CNS Drug Rev. 2005 Autumn;11(3):273-88. doi:10.1111/j.1527-3458.2005.tb00047.x; Tellez S, Colpaert F, Marien M. Acetylcholine release in the rat prefrontal cortex in vivo: modulation by alpha 2-adrenoceptor agonists and antagonists. J Neurochem. 1997 Feb;68(2):778-85. doi:10.1046/j.1471-4159.1997.68020778.x; Scheinin M, Sallinen J, Haapalinna A. Evaluation of the alpha2C-adrenoceptor as a neuropsychiatric drug target studies in transgenic mouse models. Life Sci. 2001 Apr 6;68(19-20):2277-85. doi:10.1016/s0024-3205(01)01016-5; Rizk P, Salazar J, Raisman-Vozari R, et al. The alpha2-adrenoceptor antagonist dexefaroxan enhances hippocampal neurogenesis by increasing the survival and differentiation of new granule cells. Neuropsychopharmacology. 2006 Jun;31(6):1146-57. doi:10.1038/sj.npp.1300954; Smith L, De Salvia M, Jenner P, et al. An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets. Mov Disord. 1996 Mar;11(2):125-35. doi:10.1002/mds.870110203; Smith LA, Jackson MG, Bonhomme C, et al. Transdermal administration of piribedil reverses MPTP-induced motor deficits in the common marmoset. Clin Neuropharmacol. 2000 May-Jun;23(3):133-42. doi:10.1097/00002826-200005000-00002; Smith LA, Tel BC, Jackson MJ, et al. Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation. Mov Disord. 2002 Sep;17(5):887-901. doi:10.1002/mds.10200; Millan MJ, Cussac D, Milligan G, et al. Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization. J Pharmacol Exp Ther. 2001 Jun;297(3):876-87.; Turle-Lorenzo N, Maurin B, Puma C, et al. The dopamine agonist piribedil with L-DOPA improves attentional dysfunction: relevance for Parkinson’s disease. J Pharmacol Exp Ther. 2006 Nov;319(2):914-23. doi:10.1124/jpet.106.109207. Epub 2006 Aug 18.; Flynn DD, Mash DC. Characterization of L-[3H]nicotine binding in human cerebral cortex: comparison between Alzheimer’s disease and the normal. J Neurochem. 1986;47:1948-54.; Marighetto A, Valerio S, Philippin JN, et al. Comparative effects of the dopaminergic agonists piribedil and bromocriptine in three different memory paradigms in rodents. J Psychopharmacol. 2008 Jul;22(5):511-21. doi:10.1177/0269881107083836. Epub 2008 Feb 28.; Brocco M, Dekeyne A, Papp M, et al. Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors. Behav Pharmacol. 2006 Nov;17(7):559-72. doi:10.1097/01.fbp.0000236267.41806.5b; Thobois S, Lhommee E, Klinger H, et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain. 2013 May;136(Pt 5):1568-77. doi:10.1093/brain/awt067. Epub 2013 Mar 29.; Eggert K, Ohlwein C, Kassubek J, et al. Influence of the nonergot dopamine agonist piribedil on vigilance in patients With Parkinson Disease and excessive daytime sleepiness (PiViCog-PD): an 11-week randomized comparison trial against pramipexole and ropinirole. Clin Neuropharmacol. 2014 JulAug;37(4):116-22. doi:10.1097/WNF.0000000000000041; Peretti CS, Gierski F, Harrois S. Cognitive skill learning in healthy older adults after 2 months of double-blind treatment with piribedil. Psychopharmacology. 2004 Nov;176(2):175-81. doi:10.1007/s00213-004-1869-8. Epub 2004 May 12.; Schuck S, Bentue-Ferrer D, Kleinermans D, et al. Psychomotor and cognitive effects of piribedil, a dopamine agonist, in young healthy volunteers. Fundam Clin Pharmacol. 2002 Feb;16(1):57-65. doi:10.1046/j.1472-8206.2002.00070.x; Straka I, Minar M, Skorvanek M, et al. Adherence to Pharmacotherapy in Patients With Parkinson's Disease Taking Three and More Daily Doses of Medication. Front Neurol. 2019 Jul 31;10:799. doi:10.3389/fneur.2019.00799. eCollection 2019.; Daley DJ, Myint PK, Gray RJ, Deane KH. Systematic review on factors associated with medication non-adherence in Parkinson's disease. Parkinsonism Relat Disord. 2012 Dec;18(10):1053-61. doi:10.1016/j.parkreldis.2012.09.004. Epub 2012 Sep 28.; https://nnp.ima-press.net/nnp/article/view/1869

الاتاحة: https://nnp.ima-press.net/nnp/article/view/1869
https://doi.org/10.14412/2074-2711-2022-4-103-107

المؤلفون: E. Vasenina E., O. Gankina A., O. Levin S., Е. Васенина Е., О. Ганькина А., О. Левин С.

المصدر: Meditsinskiy sovet = Medical Council; № 2 (2022); 86-93 ; Медицинский Совет; № 2 (2022); 86-93 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: dopamine receptor agonists, Parkinson’s disease, application, possibilities, ropinirole, non-motor symptoms, агонисты дофаминовых рецепторов, болезнь Паркинсона, применение, возможности, ропинирол, немоторные симптомы

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/6739/6082; Левин О.С., Чимагомедова А.Ш., Яковлева О.В. Мифология болезни Паркинсона: от леводопофобии к агонистофобии. Медицинский совет. 2020;(19):31–40. https://doi.org/10.21518/2079-701X-2020-19-31-40.; Левин О.С. Долгосрочная дофаминергическая терапия болезни Паркинсона. Медицинский совет. 2017;(10):74–80. https://doi.org/10.21518/2079-701X-2017-10-74-80.; Левин О.С., Артемьев Д.В., Бриль Е.В., Кулуа Т.К. Болезнь Паркинсона: современные подходы к диагностике и лечению. Практическая медицина. 2017;1(1):45–51. Режим доступа: http://pmarchive.ru/el-arxiv/arxiv-za-2017-god/prakticheskaya-medicina-1-102-2017-nevrologiya-2/.; Garcia-Ruiz P., Martinez Castrillo J., Desojo L. Creativity related to dopaminergic treatment: A multicenter study. Parkinsonism Relat Disord. 2019;63:169–173. https://doi.org/10.1016/j.parkreldis.2019.02.010.; Moore T.J., Glenmullen J., Mattison D.R. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med. 2014;174(12):1930–1933. https://doi.org/10.1001/jamainternmed.2014.5262.; Garcia-Ruiz P.J., Martinez Castrillo J.C., Alonso-Canovas A., Herranz Barcenas A., Vela L., Sanchez Alonso P. et al. Impulse control disorder in patients with Parkinson’s disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry. 2014;85(8):840–844. https://doi.org/10.1136/jnnp-2013-306787.; Garcia-Ruiz P. Impulse Control Disorders and Dopamine-Related Creativity: Pathogenesis and Mechanism, Short Review, and Hypothesis. Front Neurol. 2018;9:1041. https://doi.org/10.3389/fneur.2018.01041.; Seeman P. Parkinson’s disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse. 2015;69(4):183–189. https://doi.org/10.1002/syn.21805.; Gershon A., Amiaz R., Shem-David H., Grunhaus L. Ropinirole Augmentation for Depression: A Randomized Controlled Trial Pilot Study. J Clin Psychopharmacol. 2019;39(1):78–81. https://doi.org/10.1097/JCP.0000000000000984.; Capote H., Rainka M., Westphal E., Beecher J., Gengo F. Ropinirole in Bipolar Disorder: Rate of Manic Switching and Change in Disease Severity. Perspect Psychiatr Care. 2018;54(2):100–106. https://doi.org/10.1111/ppc.12205.; Taylor W., Zald D., Felger J., Christman S., Claassen D., Horga G. et al. Influences of dopaminergic system dysfunction on late-life depression. Mol Psychiatry. 2021;10.1038/s41380-021-01265-0. https://doi.org/10.1038/s41380-021-01265-0.; Dionys V., Sienaert P. Pramipexole in bipolar depression: a literature review and clinical recommendations. Tijdschr Psychiatr. 2021;63(9):658–664. (In Dutch) Available at: http://www.tijdschriftvoorpsychiatrie.nl/assets/articles/63-2021-9-artikel-dionys.pdf.; Jiang D., Jiang L., Wang Y., Li M. The role of pramipexole in the treatment of patients with depression and Parkinson’s disease: A meta-analysis of randomized controlled trials. Asian J Psychiatr. 2021;61:102691. https://doi.org/10.1016/j.ajp.2021.102691.; Taguchi S., Koide H., Oiwa H., Hayashi M., Ogawa K., Ito C. et al. Antiparkinsonian drugs as potent contributors to nocturnal sleep in patients with Parkinson’s disease. PLoS ONE. 2021;16(7):e0255274. https://doi.org/10.1371/journal.pone.0255274.; Gossard T.R., Trotti L.M., Videnovic A., St Louis E.K. Restless Legs Syndrome: Contemporary Diagnosis and Treatment. Neurotherapeutics. 2021;18(1):140–155. https://doi.org/10.1007/s13311-021-01019-4.; Koo B. Restless Leg Syndrome Across the Globe: Epidemiology of the Restless Legs Syndrome/Willis-Ekbom Disease. Sleep Med Clin. 2015;10(3):189–205. https://doi.org/10.1016/j.jsmc.2015.05.004.; Ахмадулина А.О., Левин О.С., Полуэктов М.Г. Синдром беспокойных ног при болезни Паркинсона. Журнал неврологии и психиатрии им. С.С. Корсакова. 2020;120(10–2):80–88. https://doi.org/10.17116/jnevro202012010280.; Turrini A., Raggi A., Calandra-Buonaura G., Martinelli P., Ferri R., Provini F. Not only limbs in atypical restless legs syndrome. Sleep Med Rev. 2018;38:50–55. https://doi.org/10.1016/j.smrv.2017.03.007.; Yulug B., Hanoglu L. Pramipexole Responsive Neck Numbness: The Therapeutic Role of Dopamine Agonists in the Spinal Cord Indicating to a Common Spinal Pathophysiology with Restless Leg Syndrome (RLS)? Curr Clin Pharmacol. 2016;11(3):221–222. https://doi.org/10.2174/1574884711666160719162015.; McCall C.A., Winkelman J.W. Respiratory-Related Leg Movements of Sleep Are Associated With Serotonergic Antidepressants But Not Bupropion. J Clin Sleep Med. 2018;14(9):1569–1576. https://doi.org/10.5664/jcsm.7338.; Sałat K., Furgała-Wojas A. Serotonergic Neurotransmission System Modulator, Vortioxetine, and Dopaminergic D2/D3 Receptor Agonist, Ropinirole, Attenuate Fibromyalgia-Like Symptoms in Mice. Molecules. 2021;26(8):2398. https://doi.org/10.3390/molecules26082398.; Lindenbach D., Das B., Conti M., Meadows S., Dutta A., Bishop C. D-512, a novel dopamine D2/3 receptor agonist, demonstrates greater antiParkinsonian efficacy than ropinirole in Parkinsonian rats. Br J Pharmacol. 2017;174(18):3058–3071. https://doi.org/10.1111/bph.13937.; Pehrson A., Jeyarajah T., Sanchez C. Regional distribution of serotonergic receptors: a systems neuroscience perspective on the downstream effects of the multimodal-acting antidepressant vortioxetine on excitatory and inhibitory neurotransmission. CNS Spectr. 2016;21(2):162–183. https://doi.org/10.1017/S1092852915000486.; Mohee A., Bretsztajn L., Eardley I. The evaluation of apomorphine for the treatment of erectile dysfunction. Expert Opin Drug Metab Toxicol. 2012;8(11):1447–1453. https://doi.org/10.1517/17425255.2012.727797.; Mulhall J. Sublingual apomorphine for the treatment of erectile dysfunction. Expert Opin Investig Drugs. 2002;11(2):295–302. https://doi.org/10.1517/13543784.11.2.295.; Guillén V., Rueda J., Lopez-Argumedo M., Solà I., Ballesteros J. Apomorphine for the Treatment of Erectile Dysfunction: Systematic Review and MetaAnalysis. Arch Sex Behav. 2020;49(8):2963–2979. https://doi.org/10.1007/s10508-020-01817-5.; Motyl J., Przykaza Ł., Boguszewski P., Kosson P., Strosznajder J. Pramipexole and Fingolimod exert neuroprotection in a mouse model of Parkinson’s disease by activation of sphingosine kinase 1 and Akt kinase. Neuropharmacology. 2018;135:139–150. https://doi.org/10.1016/j.neuropharm.2018.02.023.; Cooper J., Van Raamsdonk J. Modeling Parkinson’s Disease in C. elegans. J Parkinsons Dis. 2018;8(1):17–32. https://doi.org/10.3233/JPD-171258.; Sarkar S., Feany M. Precision Medicine on the Fly: Using Drosophila to Decipher Gene-Environment Interactions in Parkinson’s Disease. Toxicol Sci. 2021;182(2):159–167. https://doi.org/10.1093/toxsci/kfab060.; Varga S., Qi C., Podolsky E., Lee D. A new Drosophila model to study the interaction between genetic and environmental factors in Parkinson’s disease. Brain Res. 2014;1583:277–286. https://doi.org/10.1016/j.brainres.2014.08.021.; Naz F., Rahul, Fatima M., Naseem S., Khan W., Mondal A., Siddique Y. Ropinirole silver nanocomposite attenuates neurodegeneration in the transgenic Drosophila melanogaster model of Parkinson’s disease. Neuropharmacology. 2020;177:108216. https://doi.org/10.1016/j.neuropharm.2020.108216.; Takahashi S., Morimoto S., Okano H. Ropinirole Hydrochloride, a Candidate Drug for ALS Treatment. Brain Nerve. 2019;71(9):943–952. https://doi.org/10.11477/mf.1416201386.; Morimoto S., Takahashi S., Fukushima K., Saya H., Suzuki N., Aoki M. et al. Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis – Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial). Regen Ther. 2019;11:143–166. https://doi.org/10.1016/j.reth.2019.07.002.; Okano H., Yasuda D., Fujimori K., Morimoto S., Takahashi S. Ropinirole, a New ALS Drug Candidate Developed Using iPSCs. Trends Pharmacol Sci. 2020;41(2):99–109. https://doi.org/10.1016/j.tips.2019.12.002.; Takahashi S., Morimoto S., Fukushima K., Nakahara J., Okano H. Ropinirole Hydrochloride for ALS. Brain Nerve. 2019;71(11):1279–1288. https://doi.org/10.11477/mf.1416201438.; Salman M., Tabassum H., Parvez S. Nrf2/HO-1 mediates the neuroprotective effects of pramipexole by attenuating oxidative damage and mitochondrial perturbation after traumatic brain injury in rats. Dis Model Mech. 2020;13(8):dmm045021. https://doi.org/10.1242/dmm.045021.; Dudhipala N., Gorre T. Neuroprotective Effect of Ropinirole Lipid Nanoparticles Enriched Hydrogel for Parkinson’s Disease: In Vitro, Ex Vivo, Pharmacokinetic and Pharmacodynamic Evaluation. Pharmaceutics. 2020;12(5):448. https://doi.org/10.3390/pharmaceutics12050448.; Andrabi S., Ali M., Tabassum H., Parveen S., Parvez S. Pramipexole prevents ischemic cell death via mitochondrial pathways in ischemic stroke. Dis Model Mech. 2019;12(8):dmm033860. https://doi.org/10.1242/dmm.033860.; Andrabi S., Tabassum H., Parveen S., Parvez S. Ropinirole induces neuroprotection following reperfusion-promoted mitochondrial dysfunction after focal cerebral ischemia in Wistar rats. Neurotoxicology. 2020;77:94–104. https://doi.org/10.1016/j.neuro.2019.12.004.; Sanderson T., Reynolds C., Kumar R., Przyklenk K., Hüttemann M. Molecular mechanisms of ischemia-reperfusion injury in brain: pivotal role of the mitochondrial membrane potential in reactive oxygen species generation. Mol Neurobiol. 2013;47(1):9–23. https://doi.org/10.1007/s12035-012-8344-z.; https://www.med-sovet.pro/jour/article/view/6739

الاتاحة: https://www.med-sovet.pro/jour/article/view/6739
https://doi.org/10.21518/2079-701X-2022-16-2-86-93

المؤلفون: CALDAROV, Anastasia, GAVRILIUC, Olga, ROTARU, Lilia, ANDRUSHKA, Alexandr, FALA, Paula

المصدر: Bulletin of the Academy of Sciences of Moldova. Medical Sciences; Vol. 71 No. 3 (2021): Medical Sciences; 30-34 ; Buletinul Academiei de Științe a Moldovei. Științe medicale; Vol. 71 Nr. 3 (2021): Ştiinţe medicale; 30-34 ; Вестник Академии Наук Молдовы. Медицина; Том 71 № 3 (2021): Медицина; 30-34 ; 1857-0011 ; 10.52692/1857-0011.2021.3-71

مصطلحات موضوعية: болезнь Паркинсона, немоторные симптомы, анемия, рак, сопутствующие заболевания, депрессия, диабет, boala Parkinson, simptome non-motorii, anemie, cancer, comorbidități, depresie, diabet, Parkinson’s disease, non-motor symptoms, anemia, comorbidities, depression, diabetes, Maladie de Parkinson, symptômes non moteurs, anémie, comorbidités, dépression, diabète

وصف الملف: application/pdf

Relation: https://bulmed.md/bulmed/article/view/3346/3350; https://bulmed.md/bulmed/article/view/3346

الاتاحة: https://bulmed.md/bulmed/article/view/3346
https://doi.org/10.52692/1857-0011.2021.3-71.25

المؤلفون: O. Druzhinina A., N. Zhukova G., L. Shperling P., D. Novotnyi A., О. Дружинина А., Н. Жукова Г., Л. Шперлинг П., Д. Новотный A.

المصدر: Neurology, Neuropsychiatry, Psychosomatics; Vol 12, No 3 (2020); 69-74 ; Неврология, нейропсихиатрия, психосоматика; Vol 12, No 3 (2020); 69-74 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2020-3

مصطلحات موضوعية: cervical dystonia, non-motor symptoms, quality of life, comorbidity, цервикальная дистония, немоторные симптомы, качество жизни, коморбидность

وصف الملف: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/1368/1059; Залялова ЗА, Хафизова ИФ, Хаятова ЗГ. Патофизиологические основы реабилитации при цервикальной дистонии. Фараматека. 2017:(15):7-15.; Stacy M. Epidemiology, clinical presentation, and diagnosis of cervical dystonia. Neurol Clin. 2008 May;26 Suppl 1:23-42. doi:10.1016/s0733-8619(08)80003-5.; Martikainen KK, Luukkaala TH, Marttila RJ. Working capacity and cervical dystonia. Parkinsonism Relat Disord. 2010 Mar;16(3): 215-7. doi:10.1016/j.parkreldis.2009.07.006. Epub 2009 Aug 5.; Ortiz RM, Scheperjans F, Mertsalmi T, et al. Comorbidity and retirement in cervical dystonia. J Neurol. 2019 Sep;266(9):2216-23. doi:10.1007/s00415-019-09402-0. Epub 2019 May 31.; Albanese A, Bhatia K, Bressman SB. Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2013 Jun 15;28(7):863-73. doi:10.1002/mds.25475. Epub 2013 May 6.; Reichel G, Stenner A, Jahn A. Zur Pha no-menologie der zervikalen Dystonien. Fortschr Neurol Psychiatr. 2009 May;77(5):272-7. doi:10.1055/s-0028-1109416. Epub 2009 May 5.; Орлова ОР. Фокальные дистонии: современные подходы к диагностике и возможности ботулинотерапии. Нервные болезни. 2016;(4):3-13.; Jinnah HA, Comella CL, Perlmutter J, et al. Longitudinal studies of botulinum toxin in cervical dystonia: Why do patients discontinue therapy? Toxicon. 2018 Jun 1;147:89-95. doi:10.1016/j.toxicon.2017.09.004. Epub 2017 Sep 6.; Girach A, Vinagre Aragon A, Zis P. Quality of life in idiopathic dystonia: a systematic review. J Neurol. 2019 Dec;266(12):2897-2906. doi:10.1007/s00415-018-9119-x. Epub 2018 Nov 20.; Comella C, Bhatia K. An international survey of patients with cervical dystonia. J Neurol. 2015;262(4):837-48. doi:10.1007/s00415-014-7586-2. Epub 2015 Jan 22.; Bezerra ME, Rocha-Filho PA. Headache Attributed to Craniocervical Dystonia — A Little Known Headache. Headache. 2017 Feb;57(2): 336-343. doi:10.1111/head.12996. Epub 2016 Dec 2.; Yang J, Shao N, Song W, et al. Nonmotor symptoms in primary adult-onset cervical dystonia and blepharospasm. Brain Behav. 2016 Dec 18;7(2):e00592. doi:10.1002/brb3.592. eCollection 2017 Feb.; Fabbrini G, Berardelli I, Moretti G, et al. Psychiatric disorders in adult-onset focal dystonia: a case-control study. Mov Disord. 2010 Mar 15;25(4):459-65. doi:10.1002/mds.22983.; Суворова ВА, Антипенко ЕА. Терапия астеноневротического синдрома у пациентов с фокальными мышечными дистониями. Журнал неврологии и психиатрии им. С.С. Корсакова. 2018;118(3):56-8.; Гусев ЕИ, редактор. Клинические рекомендации по диагностике и лечению дистонии. Москва; 2014. С. 20-4.; Logroscino G, Livrea P, Anaclerio D, et al. Agreement among neurologists on the clinical diagnosis of dystonia at different body sites. J Neurol Neurosurg Psychiatry. 2003 Mar;74(3): 348-50. doi:10.1136/jnnp.74.3.348.; Charles PD, Adler CH, Stay M, et al. Cervical dystonia and pain: characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observastion of OnabotulinumtoxinA Efficacy). J Neurol. 2014 Jul;261(7):1309-19. doi:10.1007/s00415-014-7343-6. Epub 2014 Apr 22.; Phukan J, Albanese A, Gasser T. Primary dystonia and dystonia-plus syndromes: clinical characteristics, diagnosis, and pathogenesis. Lancet Neurol. 2011 Dec;10(12):1074-85. doi:10.1016/S1474-4422(11)70232-0. Epub 2011 Oct 24.; Voon V, Butler TR, Ekanayake V, et al. Psychiatric symptoms associated with focal hand dystonia. Mov Disord. 2010 Oct 15;25(13): 2249-52. doi:10.1002/mds.23250.; Smit M, Kuiper A, Han V, et al. Psychiatric co-morbidity is highly prevalent in idiopathic cervical dystonia and significantly influences health-related quality of life: Results of a controlled study. Parkinsonism and Related Disorders.2016. Sep;30:7-12. doi:10.1016/j.parkreldis.2016.06.004.; Ribot B, Aupy J, Vidailhet M, et al. Dystonia and dopamine: from phenomenology to pathophysiology. Prog Neurobiol. 2019 Nov; 182:101678. doi:10.1016/j.pneurobio.2019.101678. Epub 2019 Aug 9.; Bedarf J, Kebir S, Michelis J, et al. Depression in blepharospasm: a question of facial feedback? Neuropsychiatr Dis Treat. 2017 Jul 14;13:1861-65. doi:10.2147/NDT.S141066. eCollection 2017.; Avanzino L, Martino D, Marchese R, et al. Quality of sleep in primary focal dystonia: a case-control study. Eur J Neurol. 2010 Apr; 17(4):576-81. doi:10.1111/j.1468-1331.2009.02884.x. Epub 2009 Dec 18.; Hertenstein E, Tang NK, Bernstein CJ, et al. Sleep in patients with primary dystonia: a systematic review on the state of research and perspectives. Sleep Med Rev. 2016 Apr;26: 95-107. doi:10.1016/j.smrv.2015.04.004. Epub 2015 May 9.; Paus S, Gross J, Moll-Muller M, et al. Impaired sleep quality and restless legs syndrome in idiopathic focal dystonia: a controlled study. J Neurol. 2011 Oct;258(10):1835-40. doi:10.1007/s00415-011-6029-6. Epub 2011 Apr 16.; Smit M, Kamphuis ASJ, Bartels AL, et al. Fatigue, Sleep Disturbances, and Their Influence on Quality of Life in Cervical Dystonia Patients. Mov Disord Clin Pract. 2016 Dec 5;4(4):517-523. doi:10.1002/mdc3.12459. eCollection Jul-Aug 2017.; Shukla AW, Brown R, Heese K, et al. High rates of fatigue and sleep disturbances in dystonia. Int J Neurosci. 2016 Oct;126(10):928-35. doi:10.3109/00207454.2015.1085035. Epub 2015 Aug 19.; Soeder A, Kluger BM, Okun MS, et al. Mood and energy determinants of quality of life in dystonia. J Neurol. 2009 Jun;256(6): 996-1001. doi:10.1007/s00415-009-5060-3. Epub 2009 Mar 10.; Eichenseer SR, Stebbins GT, Comella CL. Beyond a motor disorder: a prospective evaluation of sleep quality in cervical dystonia. Parkinsonism Relat Disord. 2014 Apr;20(4): 405-8. doi:10.1016/j.parkreldis.2014.01.004. Epub 2014 Jan 15.; Pekmezovic T, Svetel M, Ivanovic N, et al. Quality of life in patients with focal dystonia. Clin Neurol Neurosurg. 2009 Feb;111(2):161-4. doi:10.1016/j.clineuro.2008.09.023. Epub 2008 Nov 7.; https://nnp.ima-press.net/nnp/article/view/1368

الاتاحة: https://nnp.ima-press.net/nnp/article/view/1368
https://doi.org/10.14412/2074-2711-2020-3-69-74

المؤلفون: E. S. Kostryukova, V. M. Alifirova, N. G. Zhukova, I. A. Zhukova, O. P. Izhboldina, V. A. Petrov, Yu. S. Mironova, A. V. Latypova, M. A. Nikitina, M. A. Titova, A. V. Tyakht, Yu. B. Dorofeeva, I. V. Saltykova, A. E. Sazonov

المصدر: Бюллетень сибирской медицины, Vol 15, Iss 5, Pp 66-74 (2017)

مصطلحات موضوعية: болезнь паркинсона, немоторные симптомы, обоняние, микробиота, Medicine

وصف الملف: electronic resource

Relation: https://bulletin.ssmu.ru/jour/article/view/735; https://doaj.org/toc/1682-0363; https://doaj.org/toc/1819-3684

URL الوصول: https://doaj.org/article/45af733d211c40878495da6668c708f2

المؤلفون: Chernavskih, Ya. O., Shcherbakova, K. Yu., Tsyganenko, O. V., Volkova, L. I., Чернавских, Я. О., Щербакова, К. Ю., Цыганенко, О. В., Волкова, Л. И.

المصدر: Сборник статей

مصطلحات موضوعية: PARKINSON'S DISEASE, NON-MOTOR SYMPTOMS, COGNITIVE IMPAIRMENT, ANXIETY LEVELS, БОЛЕЗНЬ ПАРКИНСОНА, НЕМОТОРНЫЕ СИМПТОМЫ, КОГНИТИВНЫЕ НАРУШЕНИЯ, УРОВЕНЬ ТРЕВОЖНОСТИ

وصف الملف: application/pdf

Relation: Актуальные вопросы современной медицинской науки и здравоохранения: сборник статей IV Международной научно-практической конференции молодых учёных и студентов, IV Всероссийского форума медицинских и фармацевтических вузов «За качественное образование», (Екатеринбург, 10-12 апреля 2019): в 3-х т. - Екатеринбург: УГМУ, CD-ROM.; Распространенность немоторных симптомов у пациентов с болезнью Паркинсона. / Я. О. Чернавских, К. Ю. Щербакова, О. В. Цыганенко, Л. И. Волкова // Актуальные вопросы современной медицинской науки и здравоохранения: сборник статей IV Международной научно-практической конференции молодых учёных и студентов, IV Всероссийского форума медицинских и фармацевтических вузов «За качественное образование», (Екатеринбург, 10-12 апреля 2019): в 3-х т. - Екатеринбург: УГМУ, CD-ROM. – 2019. – Т.2. – С. 280-285.; http://elib.usma.ru/handle/usma/4136

الاتاحة: http://elib.usma.ru/handle/usma/4136

مصطلحات موضوعية: Parkinson disease, болезнь Паркинсона, тревога, иглорефлексотерапия, yoga, cognitive-behavioural therapy, йога, немоторные симптомы, anxiety, когнитивно-поведенческая терапия, non-motor symptoms, acupuncture

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::1695c732f06768e97f3ad6192557249e

المؤلفون: Alifirova V.M., Zhukova N.G., Zhukova I.A., Mironova Y.S., Petrov V.A., Izhboldina O.P., Titova M.A., Latypova A.V., Nikitina M.A., Dorofeeva Y.B., Saltykova I.V., Tyakht A.V., Kostryukova E.S., Sazonov A.E.

المصدر: Annals of the Russian academy of medical sciences; Vol 71, No 6 (2016) ; Вестник Российской академии медицинских наук; Vol 71, No 6 (2016) ; 2414-3545 ; 0869-6047 ; 10.15690/vramn716

مصطلحات موضوعية: Parkinson’s disease, nonmotor symtoms, anxiety, depression, microbiota, болезнь Паркинсона, немоторные симптомы, тревога, депрессия, микробиота

وصف الملف: application/pdf

Relation: https://vestnikramn.spr-journal.ru/jour/article/view/734/714; https://vestnikramn.spr-journal.ru/jour/article/view/734

الاتاحة: https://vestnikramn.spr-journal.ru/jour/article/view/734
https://doi.org/10.15690/vramn734

المصدر: Current issues in pharmacy and medicine: science and practice; Vol. 14 No. 3 (2021); 382-389
Актуальные вопросы фармацевтической и медицинской науки и практики; Том 14 № 3 (2021); 382-389
Актуальні питання фармацевтичної та медичної науки та практики; Том 14 № 3 (2021); 382-389

مصطلحات موضوعية: когнитивные и ментальные нарушения, хвороба Паркінсона, реабилитация, немоторні симптоми, cognitive and mental disorders, non-motor symptoms, rehabilitation, эрготерапия, когнітивні та ментальні порушення, болезнь Паркинсона, occupational therapy, Parkinson’s disease, ерготерапія, немоторные симптомы, реабілітація

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=scientific_p::06b86e152edb652948e07b2793021971
http://pharmed.zsmu.edu.ua/article/view/239791

المؤلفون: ГОНЧАРОВА З.А., РАБАДАНОВА Е.А., ГЕЛЬПЕЙ М.А.

مصطلحات موضوعية: БОЛЕЗНЬ ПАРКИНСОНА,PARKINSON'S DISEASE,НЕМОТОРНЫЕ СИМПТОМЫ,NON-MOTOR SYMPTOMS,КАЧЕСТВО ЖИЗНИ,QUALITY OF LIFE

وصف الملف: text/html

الاتاحة: http://cyberleninka.ru/article/n/enemotornye-proyavleniya-bolezni-parkinsonai-ih-vliyanie-na-kachestvo-zhizni-patsientov
http://cyberleninka.ru/article_covers/16976868.png

المؤلفون: РАБАДАНОВА Е.А., ГЕЛЬПЕЙ М.А., ГОНЧАРОВА З.А.

مصطلحات موضوعية: БОЛЕЗНЬ ПАРКИНСОНА,НЕМОТОРНЫЕ СИМПТОМЫ,КАЧЕСТВО ЖИЗНИ,PARKINSON''S DISEASE,NON-MOTOR SYMPTOMS,QUALITY OF LIFE

وصف الملف: text/html

الاتاحة: http://cyberleninka.ru/article/n/nemotornye-simptomy-bolezni-parkinsona-ih-struktura-i-vliyanie-na-kachestvo-zhizni-patsientov
http://cyberleninka.ru/article_covers/16376553.png

المؤلفون: Радюк, Михаил, Светозарский, Сергей, Копишинская, Светлана

مصطلحات موضوعية: НЕМОТОРНЫЕ СИМПТОМЫ, БОЛЕЗНЬ ПАРКИНСОНА, ШКАЛЫ ОЦЕНКИ НЕМОТОРНЫХ СИМПТОМОВ, НЕМОТОРНЫЕ ФЛЮКТУАЦИИ, PARKINSON’S DISEASE

وصف الملف: text/html

الاتاحة: http://cyberleninka.ru/article/n/nemotornye-proyavleniya-bolezni-parkinsona-1
http://cyberleninka.ru/article_covers/15632045.png

المؤلفون: Y. I. Golovchenko, V. V. Kostenko

المصدر: Ukrainian Neurological Journal; № 3 (2020); 35—40
Украинский неврологический журнал; № 3 (2020); 35—40
Український неврологічний журнал; № 3 (2020); 35—40

مصطلحات موضوعية: medicine.anatomical_structure, business.industry, medicine, бічний аміотрофічний склероз, немоторні симптоми, шкала немоторних симптомів, хвороба рухового нейрона, Non motor, amyotrophic lateral sclerosis, non‑motor symptoms, non‑motor symptomsscale, Disease, Motor neuron, business, Neuroscience, боковой амиотрофический склероз, немоторные симптомы, шкала немоторных симптомов

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9dd172eb85db059f82a47e9bc7df6b4
http://ukrneuroj.com.ua/article/view/UNJ2020-3-35

المؤلفون: ПОНОМАРЁВ В.В., МАЗУРЕНКО Е.В.

مصطلحات موضوعية: БОЛЕЗНЬ ПАРКИНСОНА,PARKINSON' DISEASE,ПРЕМОТОРНАЯ ФАЗА,PREMOTOR PHASE,НЕМОТОРНЫЕ СИМПТОМЫ,NON-MOTOR SYMPTOMS

وصف الملف: text/html

الاتاحة: http://cyberleninka.ru/article/n/diagnostika-bolezni-parkinsona-na-rannih-stadiyah-zabolevaniya
http://cyberleninka.ru/article_covers/16392695.png

المؤلفون: САДОХА К.А., МАЗУРЕНКО Е.В.

مصطلحات موضوعية: БОЛЕЗНЬ ПАРКИНСОНА,PARKINSON'S DISEASE,ПРЕМОТОРНАЯ ФАЗА,PREMOTOR PHASE,НЕМОТОРНЫЕ СИМПТОМЫ,NON-MOTOR SYMPTOMS

وصف الملف: text/html

الاتاحة: http://cyberleninka.ru/article/n/bolezn-parkinsona-nekotorye-aspekty-patogeneza-i-effektivnoe-lechenie
http://cyberleninka.ru/article_covers/16392868.png

المؤلفون: ТОРГАН ТАТЬЯНА ИВАНОВНА

مصطلحات موضوعية: БОЛЕЗНЬ ПАРКИНСОНА,PARKINSON'S DISEASE,НЕМОТОРНЫЕ СИМПТОМЫ,NONMOTOR SYMPTOMS,FATIGUABILITY,КАЧЕСТВО ЖИЗНИ,QUALITY OF LIFE,УТОМЛЯЕМОСТЬ

وصف الملف: text/html

الاتاحة: http://cyberleninka.ru/article/n/sindrom-utomlyaemosti-i-drugie-nemotornye-simptomy-bolezni-parkinsona-i-ih-vliyanie-na-kachestvo-zhizni
http://cyberleninka.ru/article_covers/16466310.png

المؤلفون: Вострикова, Елена, Щепанкевич, Лариса, Пилипенко, Павел, Ахундова, Лейла, Мясникова, Наталья, Кононова, Елена, Федорова, Кристина

مصطلحات موضوعية: БОЛЕЗНЬ ПАРКИНСОНА, НЕМОТОРНЫЕ СИМПТОМЫ, ПСИХОТИЧЕСКИЕ НАРУШЕНИЯ, ЗРИТЕЛЬНЫЕ ГАЛЛЮЦИНАЦИИ, PARKINSON'S DISEASE

وصف الملف: text/html

الاتاحة: http://cyberleninka.ru/article/n/klinicheskaya-harakteristika-zritelnyh-narusheniy-pri-bolezni-parkinsona
http://cyberleninka.ru/article_covers/14342152.png

المؤلفون: Литвиненко, Игорь, Данилкина, Маргарита

مصطلحات موضوعية: ПОВРЕЖДЕННОЕ РАЗВИТИЕ, ДЕМЕНЦИЯ, НЕМОТОРНЫЕ СИМПТОМЫ, КОГНИТИВНЫЕ НАРУШЕНИЯ, ПСИХОТИЧЕСКИЕ НАРУШЕНИЯ, НАРУШЕНИЯ СНА

وصف الملف: text/html

الاتاحة: http://cyberleninka.ru/article/n/proyavleniya-kognitivnyh-i-nemotornyh-narusheniy-pri-povrezhdennom-psihicheskom-razvitii-dementsii
http://cyberleninka.ru/article_covers/14857362.png